Bendamustine-Rituximab

by suka farmasi on August 02, 2015

Pharmacologic Category

Chemotherapy Regimen, Lymphoma, non-Hodgkin's

Regimen Use

Lymphoma, non-Hodgkin's (Mantle cell or low-grade NHL)

Index Terms

Rituximab-Bendamustine

Regimen

NOTE: Multiple variations are listed below.

Variation 1:

Pretreatment:

Rituximab: I.V.: 375 mg/m2 1 week before the start of cycle 1

[total dose/pretreatment = 375 mg/m2]

Cycles:

Rituximab: I.V.: 375 mg/m2 day 1

[total dose/cycle = 375 mg/m2]

Bendamustine: I.V.: 90 mg/m2 days 2 and 3

[total dose/cycle = 180 mg/m2]

Repeat cycle every 4 weeks for up to 4 cycles

Post-Treatment:

Rituximab: I.V.: 375 mg/m2 4 weeks after the last cycle

[total dose/post-treatment = 375 mg/m2]

Variation 2:

Pretreatment:

Rituximab: I.V.: 375 mg/m2 1 week before the start of cycle 1

[total dose/pretreatment = 375 mg/m2]

Cycles:

Rituximab: I.V.: 375 mg/m2 day 1

[total dose/cycle = 375 mg/m2]

Bendamustine: I.V.: 90 mg/m2 days 2 and 3

[total dose/cycle = 180 mg/m2]

Repeat cycle every 4 weeks for 4-6 cycles

Post-Treatment:

Rituximab: I.V.: 375 mg/m2 4 weeks after the last cycle

[total dose/post-treatment = 375 mg/m2]

References

Variation 1:

Rummel MJ, Al-Batran SE, Kim SZ, et al, "Bendamustine Plus Rituximab Is Effective and Has a Favorable Toxicity Profile in the Treatment of Mantle Cell and Low-Grade Non-Hodgkin's Lymphoma," J Clin Oncol, 2005, 23(15):3383-9.[PubMed 15908650]

Variation 2:

Robinson KS, Williams ME, van der Jagt RH, et al, "Phase II Multicenter Study of Bendamustine Plus Rituximab in Patients With Relapsed Indolent B-Cell and Mantle Cell Non-Hodgkin's Lymphoma," J Clin Oncol, 2008, 26(27):4473-9.[PubMed 18626004]